RedHill Biopharma Receives FDA Acceptance for New Drug Application of Talicia

- July 3rd, 2019

RedHill Biopharma (NASDAQ:RDHL) has announced that the US Food and Drug Administration (FDA) has accepted its Talicia new drug application for review. As quoted in the press release: The NDA for Talicia has also been granted Priority Review designation and was assigned a target Prescription Drug User Act (PDUFA) action date by the FDA of … Continued

RedHill Biopharma (NASDAQ:RDHL) has announced that the US Food and Drug Administration (FDA) has accepted its Talicia new drug application for review.

As quoted in the press release:

The NDA for Talicia has also been granted Priority Review designation and was assigned a target Prescription Drug User Act (PDUFA) action date by the FDA of November 2, 2019.

Priority Review is a designation granted by the FDA to prioritize the review process for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment of serious conditions when compared to standard applications.

Commercial launch of Talicia with RedHill’s existing U.S. sales force is planned shortly following potential FDA approval.

If approved, Talicia would be eligible for a total of eight years of U.S. market exclusivity.

H. pylori bacterial infection affects more than 50% of the population worldwide2 and approximately 35% of the U.S. population3. It is classified as a Group I carcinogen and is the strongest risk factor for the development of gastric cancer2 and a major risk factor for peptic ulcer disease4 and gastric mucosa-associated lymphoid tissue (MALT) lymphoma5H. pylori-infected persons have a 6-fold increased risk of developing non-cardia gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma4.

Click here to read the full press release.

Is the biotech market the perfect mesh between the technology and pharmaceutical market?

 
Read our FREE outlook report below!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply

Your email address will not be published. Required fields are marked *